title: Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.
abstract: OBJECTIVE
  To compare the pharmacokinetic profiles of beclometasone, budesonide, fluticasone and mometasone following inhalation in patients with asthma, and explore the relationship between lung function and plasma drug concentrations.
  
  
  METHODS
  Thirty subjects with asthma and a forced expiratory volume in 1 s (FEV(1)) ranging from 36 to 138% predicted, inhaled 800 microg beclometasone, budesonide and mometasone and 1000 microg fluticasone in random order. Plasma drug concentrations were measured over 8 h and the relationship between the area under the plasma concentration-time curve (AUC(0-8)) and lung function was modelled using linear regression. Estimated AUC(0-8) values at 50 and 100% predicted FEV(1) were compared for each drug.
  
  
  RESULTS
  Pharmacokinetic profiles differed markedly between the drugs. Correlation coefficients for the relation between FEV(1)% predicted and AUC(0-8) values for beclometasone, budesonide, fluticasone and mometasone were 0.37 (P = 0.05), 0.33 (P = 0.08), 0.25 (P = 0.2) and 0.52 (P = 0.004), respectively, and estimated AUC(0-8) values were 1.3 [95% confidence interval (CI) 1.0, 1.8], 1.3 (95% CI 1.0, 1.8), 1.4 (95% CI 0.9, 2.2) and 2.2 (95% CI 1.3, 3.5) times higher for the four drugs, respectively, at 100 compared with 50% predicted FEV(1.)
  
  
  CONCLUSIONS
  The higher plasma concentrations of inhaled corticosteroids in patients with a higher FEV(1)% predicted suggests that, for any given dose, these patients will be at greater risk of developing adverse systemic effects with long-term use.
authors.affiliation: Division of Respiratory Medicine, Nottingham City Hospital, University of Nottingham, Nottingham, UK. kevinmortimer@msn.com
authors.forename: Kevin J
authors.initials: KJ
authors.lastname: Mortimer
authors.forename: Tim W
authors.initials: TW
authors.lastname: Harrison
authors.forename: Yufei
authors.initials: Y
authors.lastname: Tang
authors.forename: Kai
authors.initials: K
authors.lastname: Wu
authors.forename: Sarah
authors.initials: S
authors.lastname: Lewis
authors.forename: Srikumar
authors.initials: S
authors.lastname: Sahasranaman
authors.forename: Gunther
authors.initials: G
authors.lastname: Hochhaus
authors.forename: Anne E
authors.initials: AE
authors.lastname: Tattersfield
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D014797:Vital Capacity / Q000502:physiology
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents